The Effect of Spa Treatment on Chronic Obstructive Pulmonary Disease (BPCeaux)
24. mars 2015 oppdatert av: Centre Hospitalier Universitaire de Nīmes
The primary objective of this study is to measure and compare the number of exacerbations (moderate or severe) between the two groups of randomized patients with and without thermal treatment).
An exacerbation is defined by an increase in symptoms which justifies a unscheduled medical action: increased daily treatment and / or use of corticosteroids, and / or antibiotic therapy.
Exacerbations are documented via prescriptions, hospitalisation reports or unscheduled visits.
Studieoversikt
Status
Avsluttet
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
39
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Aix les Bains, Frankrike, 73100
- Private practice: Karim Berkani
-
Amélie les Bains Palalda, Frankrike, 66110
- Private practice: Jean Hérété
-
Briey, Frankrike, 54150
- Private practice: Pierre Ethève
-
Ceret, Frankrike, 66400
- Private practice: Marc Bellier
-
Perpignan, Frankrike, 66000
- Private practice: Pierre Olivier
-
Saint Amand les Eaux, Frankrike, 59230
- Private practice: Muriel Nouvelle
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
40 år til 80 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient must have chronic obstructive pulmonary disease
- Obstructive ventilation problem: Tiffeneau index (expiratory volume in one second / slow vital capacity) < 70%
- Expiratory volume in one second < 80% of the theoretical value
- Reversibility < 12% after inhalation of bronchodilators
- Smokers or ex smokers
- Available for study monitoring
- Has access to diagnostic, medical and therapeutic care according to the best, current criteria (see the recommendations of the French Language Pseumologist Society)
Exclusion Criteria:
- The patient is participating in another study
- The patient has participated in another study in the past 12 months
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is in military service (unavailable for monitoring)
- Patient is on parole or otherwise has their liberty restricted by administrative or judiciary decision
- The patient is pregnant, or does not have contraception
- The patient is breastfeeding
- Patient has neoplastic disease
- Patient has asthma
- Patient has another, evolving pulmonary disease (tuberculosis, pulmonary interstitium disease, active or recent pulmonary infection)
- Patient has a clinical history indicating asthma or another respiratory disease (in particular bronchiectasis, pneumoconiosis and other occupational diseases, history of pulmonary neoplasia, HIV, immunosuppressive therapy including corticosteroids in the long term
- Patient has respiratory insufficiency
- Hypereosinophilic patient (the number of polynuclear eosinophils is > 0.5 giga/l; confirmed on 2 hemograms)
- Recent psychiatric trouble (less than 1 year)
- Takes illegal drugs
- Patient does not have pneumological care according to the standards set by the French Language Pneumologist Society
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Standard
The patients randomized into this arm of the study will not have spa therapy.
|
|
|
Eksperimentell: Spa Therapy
The patients randomized into this arm of the study will have 3 weeks of spa therapy
|
3 weeks of spa therapy
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of exacerbations
Tidsramme: 12 months after the beginning of treatment
|
Exacerbation = increase in symptoms (IS) justifying an unprogrammed therapeutic intervention (TI).
An IS = increase in >=2 of the following minor symptoms for >= 2 consecutive days (CD): (i) dyspnea, (ii) volume or (iii) purulence of sputum.
Or an increase in any 1 of the following major symptoms associated with any of the minor symptoms for at least 2 CD: (a) sore throat, (b) cold, (c) fever, (d) coughing, (e) wheezing.
A TI = systemic corticoids and/or antibiotics.
An exacerbation is defined as severe if TI is accompanied by a hospital stay > 24h, and as "moderate" otherwise.
|
12 months after the beginning of treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
change in the BODE score
Tidsramme: 3 weeks
|
3 weeks
|
|
|
change in SF36 questionnaire scores
Tidsramme: 3 weeks
|
the SF36 quality of life questionnaire
|
3 weeks
|
|
Cost (€)
Tidsramme: 3 weeks
|
Costs are evaluated from the point of view of payers associated with the pathology.
|
3 weeks
|
|
C reactive protein (mg/l)
Tidsramme: 3 weeks
|
blood work
|
3 weeks
|
|
Eosiniphil count (thou/ml)
Tidsramme: 3 weeks
|
blood work
|
3 weeks
|
|
Number of exacerbations
Tidsramme: 3 weeks
|
Exacerbation = increase in symptoms (IS) justifying an unprogrammed therapeutic intervention (TI).
An IS = increase in >=2 of the following minor symptoms for >= 2 consecutive days (CD): (i) dyspnea, (ii) volume or (iii) purulence of sputum.
Or an increase in any 1 of the following major symptoms associated with any of the minor symptoms for at least 2 CD: (a) sore throat, (b) cold, (c) fever, (d) coughing, (e) wheezing.
A TI = systemic corticoids and/or antibiotics.
An exacerbation is defined as severe if TI is accompanied by a hospital stay > 24h, and as "moderate" otherwise.
|
3 weeks
|
|
change in the BODE score
Tidsramme: 3 months
|
3 months
|
|
|
change in the BODE score
Tidsramme: 6 months
|
6 months
|
|
|
change in the BODE score
Tidsramme: 9 months
|
9 months
|
|
|
change in the BODE score
Tidsramme: 12 months
|
12 months
|
|
|
change in SF36 questionnaire scores
Tidsramme: 3 months
|
the SF36 quality of life questionnaire
|
3 months
|
|
change in SF36 questionnaire scores
Tidsramme: 6 months
|
the SF36 quality of life questionnaire
|
6 months
|
|
change in SF36 questionnaire scores
Tidsramme: 9 months
|
the SF36 quality of life questionnaire
|
9 months
|
|
change in SF36 questionnaire scores
Tidsramme: 12 months
|
the SF36 quality of life questionnaire
|
12 months
|
|
Cost (€)
Tidsramme: 3 months
|
Costs are evaluated from the point of view of payers associated with the pathology.
|
3 months
|
|
Cost (€)
Tidsramme: 6 months
|
Costs are evaluated from the point of view of payers associated with the pathology.
|
6 months
|
|
Cost (€)
Tidsramme: 9 months
|
Costs are evaluated from the point of view of payers associated with the pathology.
|
9 months
|
|
Cost (€)
Tidsramme: 12 months
|
Costs are evaluated from the point of view of payers associated with the pathology.
|
12 months
|
|
Number of exacerbations
Tidsramme: 3 months
|
Exacerbation = increase in symptoms (IS) justifying an unprogrammed therapeutic intervention (TI).
An IS = increase in >=2 of the following minor symptoms for >= 2 consecutive days (CD): (i) dyspnea, (ii) volume or (iii) purulence of sputum.
Or an increase in any 1 of the following major symptoms associated with any of the minor symptoms for at least 2 CD: (a) sore throat, (b) cold, (c) fever, (d) coughing, (e) wheezing.
A TI = systemic corticoids and/or antibiotics.
An exacerbation is defined as severe if TI is accompanied by a hospital stay > 24h, and as "moderate" otherwise.
|
3 months
|
|
Number of exacerbations
Tidsramme: 6 months
|
Exacerbation = increase in symptoms (IS) justifying an unprogrammed therapeutic intervention (TI).
An IS = increase in >=2 of the following minor symptoms for >= 2 consecutive days (CD): (i) dyspnea, (ii) volume or (iii) purulence of sputum.
Or an increase in any 1 of the following major symptoms associated with any of the minor symptoms for at least 2 CD: (a) sore throat, (b) cold, (c) fever, (d) coughing, (e) wheezing.
A TI = systemic corticoids and/or antibiotics.
An exacerbation is defined as severe if TI is accompanied by a hospital stay > 24h, and as "moderate" otherwise.
|
6 months
|
|
Number of exacerbations
Tidsramme: 9 months
|
Exacerbation = increase in symptoms (IS) justifying an unprogrammed therapeutic intervention (TI).
An IS = increase in >=2 of the following minor symptoms for >= 2 consecutive days (CD): (i) dyspnea, (ii) volume or (iii) purulence of sputum.
Or an increase in any 1 of the following major symptoms associated with any of the minor symptoms for at least 2 CD: (a) sore throat, (b) cold, (c) fever, (d) coughing, (e) wheezing.
A TI = systemic corticoids and/or antibiotics.
An exacerbation is defined as severe if TI is accompanied by a hospital stay > 24h, and as "moderate" otherwise.
|
9 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Studieleder: Nicolas Molinari, PhD, Centre Hospitalier Universitaire de Nîmes
- Hovedetterforsker: Jean Victor Hérété, MD, Amélie les Bains
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2011
Primær fullføring (Faktiske)
1. juni 2014
Studiet fullført (Faktiske)
1. juni 2014
Datoer for studieregistrering
Først innsendt
15. februar 2011
Først innsendt som oppfylte QC-kriteriene
15. februar 2011
Først lagt ut (Anslag)
16. februar 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
25. mars 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
24. mars 2015
Sist bekreftet
1. mars 2015
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LOCAL/2010/NM-02
- 2010-A00693-36 (Annen identifikator: RCB number)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .